Used in research and development of type 2 diabetes and obesity treatments by blocking the glucose-dependent insulinotropic polypeptide receptor (GIPR), thereby modulating insulin secretion and improving glycemic control. It serves as a reference tool in preclinical studies to evaluate the efficacy and mechanism of GIPR-targeting therapeutics, particularly in dual or multi-agonist therapies such as GLP-1/GIP receptor co-agonists. Also utilized in pharmacokinetic and pharmacodynamic assays to benchmark new antibody candidates.